Core Viewpoint - The acquisition of Crown Bioscience International by Miramar Lifesciences Limited for a total purchase price of $204 million is expected to enhance the product portfolio of the company and provide long-term strategic benefits [1][2]. Company Overview - The target company, Crown Bioscience International, is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. - The company collaborates with biotechnology and pharmaceutical firms to accelerate drug development through integrated preclinical, translational, and clinical biomarker services [1]. Strategic Rationale - The board believes that the acquisition aligns with the group's development strategy to expand its product offerings [2]. - The acquisition is anticipated to bring long-term and strategic benefits to the company [2].
艾迪康控股(09860)拟2.04亿美元收购Crown Bioscience International100%股权